Business
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026 Data from the 400 mg multidose cohort of RestorAATion-2 clinical trial remain on track for first quarter o
About this update from Wave Life Sciences Ltd.
[{"type":"image","alt":"Wave Life Sciences USA, Inc.","displaySize":"","headline":null,"caption":"Wave Life Sciences USA, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bBn7PJO.Wa13q4jNzDNEcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6","width":300,"height":161}},"lazy":false},{"type":"text","content":"WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease","length":267,"tagName":"p"},{"type":"text","content":"Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026 ","length":125,"tagName":"p"},{"type":"text","content":"Data from the 400 mg multidose cohort of RestorAATion-2 clinical trial remain on track for first quarter of 2026 and data from the 600 mg single and multidose cohorts are expected in 2026","length":187,"tagName":"p"},{"type":"text","content":"Research collaboration with GSK is ongoing and continues to expand with fourth program now selected to advance","length":110,"tagName":"p"},{"type":"text","content":"Wave continues to expect cash runway into 3Q 2028 ","length":49,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it has regained full rights to WVE-006, an investigational GalNAc-conjugated RNA editing oligonucleotide (AIMer) for alpha-1 antitrypsin deficiency (AATD), from GSK. This follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to efficiently advance the WVE-006 program in AATD, a rare condition. This agreement was made prior to data becoming available from the next cohort of the RestorAATion-2 clinical trial, which remains on track for the first quarter of 2026. Wave is now accelerating its registrational ...